Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.
- THE COMPLEX WEB OF PRESCRIPTION DRUG PRICES, PART III: EXAMINING AGENCY EFFORTS TO FURTHER COMPETITION AND INCREASE AFFORDABILITY [Senate Hearing 116-546] [From the U.S. Government Publishing Office] S. Hrg. 116-546 THE COMPLEX WEB OF PRESCRIPTION DRUG PRICES, PART III: EXAMINING AGENCY EFFORTS TO FURTHER COMPETITION AND INCREASE AFFORDABILITY ======================================================================= HEARING BEFORE THE SPECIAL COMMITTEE ON AGING UNITED STATES SENATE ONE HUNDRED SIXTEENTH CONGRESS FIRST SESSION __________ WASHINGTON, DC __________ JUNE 19, 2019 __________ Serial No. 116-08 Printed for the use of the Special Committee on Aging [GRAPHIC NOT AVAILABLE IN TIFF FORMAT] Available via the World Wide Web: http://www.govinfo.gov __________ U.S. GOVERNMENT PUBLISHING OFFICE 47-411 PDF WASHINGTON : 2022 ----------------------------------------------------------------------------------- SPECIAL COMMITTEE ON AGING SUSAN M. COLLINS, Maine, Chairman TIM SCOTT, South Carolina ROBERT P. CASEY, JR., Pennsylvania RICHARD BURR, North Carolina KIRSTEN E. GILLIBRAND, New York MARTHA McSALLY, Arizona RICHARD BLUMENTHAL, Connecticut MARCO RUBIO, Florida ELIZABETH WARREN, Massachusetts JOSH HAWLEY, Missouri DOUG JONES, Alabama MIKE BRAUN, Indiana KYRSTEN SINEMA, Arizona RICK SCOTT, Florida JACKY ROSEN, Nevada ---------- Sarah Khasawinah, Majority Acting Staff Director Kathryn Mevis, Minority Staff Director C O N T E N T S ---------- Page Opening Statement of Senator Susan M. Collins, Chairman.......... 1 Opening Statement of Senator Robert P. Casey, Jr., Ranking Member 3 PANEL OF WITNESSES Demetrios Kouzoukas, Principal Deputy Administrator and Director of the Center for Medicare, Center for Medicare and Medicaid Services, Washington, D.C...................................... 4 Janet Woodcock, M.D., Director of the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland....................................................... 6 Vicki L. Robinson, Senior Counselor for Policy, U.S. Department of Health and Human Services, Office of Inspector General, Washington, D.C................................................ 8 APPENDIX Prepared Witness Statements Demetrios Kouzoukas, Principal Deputy Administrator and Director of the Center for Medicare, Center for Medicare and Medicaid Services, Washington, D.C...................................... 35 Janet Woodcock, M.D., Director of the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland....................................................... 46 Vicki L. Robinson, Senior Counselor for Policy, U.S. Department of Health and Human Services, Office of Inspector General, Washington, D.C................................................ 55 Statements for the Record Letter to President Donald J. Trump, dated June 11, 2019......... 65 Letter to President Donald J. Trump, dated June 19, 2019......... 69 THE COMPLEX WEB OF PRESCRIPTION DRUG PRICES, PART III: EXAMINING AGENCY EFFORTS TO FURTHER COMPETITION AND INCREASE AFFORDABILITY ---------- WEDNESDAY, JUNE 19, 2019 U.S. Senate, Special Committee on Aging, Washington, DC. The Committee met, pursuant to notice, at 9 a.m., in Room 562, Dirksen Senate Office Building, Hon. Susan M. Collins, Chairman of the Committee, presiding. Present: Senators Collins, Tim Scott, McSally, Braun, Rick Scott, Casey, Blumenthal, and Jones. Also present: Senator Shaheen. OPENING STATEMENT OF SENATOR SUSAN M. COLLINS, CHAIRMAN The Chairman. The Committee will come to order. Good morning. Today we are holding the third in our current series of hearings on the complex web of prescription drug prices. We will feature witnesses from the Food and Drug Administration, better known as the FDA, the Centers for Medicare and Medicaid Services, CMS, and the Office of the Inspector General at the Department of Health and Human Services. Since 2015, our Committee has held eight hearings on drug pricing and the issue that I believe bridges the partisan divide. According to the Kaiser Family Foundation, nearly 7 in 10 Americans say that lowering prescription drug prices should be a top priority for Congress. As those who have followed our Committee's work on drug pricing know, we have highlighted example after example of patients who feel powerless when confronted with sky-high drug costs, and go to extraordinary lengths to cover the costs of their medications. In the interest of time this morning, I am only going to list one of those examples, but I will be putting others into the record as part of my full opening statement. At last year's hearing on the spike in insulin costs, we learned how rebates and the complicated supply chain create pricing distortions, particularly for those with high- deductible health plans. We heard from Paul Grant, a father of four, who lives in New Gloucester, Maine, who discovered 1 day that the cost of a 90-day supply of insulin for his 13-year-old son with type 1 diabetes had tripled overnight to more than $900. He had to resort to importing much lower-cost insulin from Canada, with no help from his insurance company. This is typical of stories that we have heard from across the country, and the American people are clamoring for action. While much more needs to be done, we have met with some successes. Following this Committee's year-long investigation into dramatic price spikes, in decades-old prescription drugs, I co-authorized a bipartisan bill with former Senator Claire McCaskill, to promote more competition from lower-priced but equally effective generic drugs. This bill was signed into law in 2017 and it appears to be showing results. To date, FDA has granted more than 100 application requests under this new pathway, with five approvals. In 2018, I authored another bipartisan bill banning pharmacy gag clauses, contract provisions that prevent pharmacists from informing consumers how to get the lowest price for their prescriptions. It became law, and a recent study published by the Journal of American Medical Association suggests that banning gag clauses could help Americans save money in nearly 1 out of 4 prescription transactions. Throughout our deliberations, I have emphasized that we want to keep strong incentives for innovation, so that companies continue to invest in research and development and take the risks necessary to develop innovative drugs, but we must do more to ensure that these essential medicines are more affordable, that their prices are more transparent, and that their competitors are not blocked once their patents have expired by gaining of the patent system. While past hearings have focused on the root causes behind escalating prices, today we will focus on some potential solutions. The timing is fortuitous, as House and Senate Committees are acting on a variety of proposals, including our bill to prevent patent gaming strategies and other approaches that delay generic or biosimilar competition, legislation to establish more price transparency, and measures to address out- of-pocket costs under Medicare Part D. Members of this Committee have been working hard on a number of promising ideas. I have introduced, along with Senator Tim Kaine, the Biological Transparency Act that would require companies to publicly disclose the web of patents that protect their biologics, making it easier for competitors to evaluate and plan for the development of generic versions, as well as to discourage late-filed patents. I am pleased that on this Committee, Senators Braun and Hawley are co-sponsors, as well as Senators Kaine, Portman, Shaheen, Stabenow, Paul, and Murkowski, who serve on other committee. Ranking Member Casey and I have partnered on legislation that he has introduced to codify the CMS drug pricing dashboards, to provide consumers with more information about out-of-pocket costs. Senator Rick Scott and I are working on legislation that creates a data base of drug prices and aggregate manufacturer rebates, as well as justifications for any price increases. One thing is certain: our drug pricing system is opaque and rife with misaligned incentives. In order to untangle patients from this complex web and bring them the relief they need without dampening R&D that produces life-saving new drugs, we need to work together, and that has been the spirit of this Committee. I am now pleased to turn to the Ranking Member, Senator Casey, for his opening remarks. OPENING STATEMENT OF SENATOR ROBERT P. CASEY, JR., RANKING MEMBER Senator Casey. Chairman Collins, thank you very much for holding this hearing on the rising cost of prescription drugs. We hear about it all the time, all across the country. With current prices, Americans are being asked to pay for their prescription drugs. Many find themselves asking, how can I make ends meet? Over and over again they ask themselves that question. That is because the rising cost of prescription drugs is not in isolation. It is part of a larger challenge many Americans face. With flat wages over many years, and high costs, the cost of prescription drugs is like a bag of rocks on the shoulders of most families. The other heavy bags of rocks on those same shoulders are the cost of child care, the cost of health care, the cost of college, and that is just to name a few. People are paying more for child care costs, and that is crushing for many families. Just as they are starting a family, that bag of rocks is dropped on their back. Then, as someone who is trying to make life better for the next generation through higher education, the cost of college increases. That is another bag of rocks. Third, just as someone is about to enter their golden years and have a secure retirement, or they hope for a secure retirement, the cost of prescription drugs skyrockets. These costs, to say the least, can be crushing. That is what we heard from Barbara Cisek from Rural Ridge, Pennsylvania, and other witnesses from across the country who testified before this Committee earlier this year. The need to make prescription drugs more affordable has never been more urgent. We will have a chance to highlight proposals under consideration in Congress, including one that Chairman Collins and I are working on, to bring greater transparency to drug pricing through the Medicare and Medicaid prescription drug dashboards. I hope we will have a chance to discuss one of my key priorities, a policy supported by 95 percent of the American people, which is to finally--finally--allow Medicare to directly negotiate the price of prescription drugs. While we hear a litany of Medicare proposals made by the Administration today, I note that not a single one of those proposals, so far, permit Medicare to use its full purchasing power to bring down the cost of prescription drugs. Indeed, it's our sacred responsibility to our aging loved ones, as well as our children and their children, that they are not forced to shoulder the crushing bag of rocks that prescription drug costs have become. I want to thank the Chairman again for scheduling this hearing about the rising cost of prescription drugs, and I look forward, as I know we all do, to getting some solutions signed into law. Thank you. The Chairman. Thank you very much, Senator Casey. I want to welcome Senator Jones and Senator Scott to the hearing as well. Our first witness today will be Demetrios Kouzoukas, the Principal Deputy Administrator and Director of the Center for Medicare, at the Center for Medicare and Medicaid Services. He will discuss the proposals within the Administration drug pricing blueprint. Next we will hear from a familiar witness to our Committee deliberations over the years, Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research at the FDA. Dr. Woodcock first joined the Center in 1994, and in 2015 was appointed to be Acting Director of its Office on Pharmaceutical Quality. Her testimony today will focus on actions the FDA has taken to improve competition in the biosimilar and generic drug marketplaces. Finally, we will hear from Vicki Robinson, the Senior Counselor for Policy at the Department of Health and Human Services, Office of the Inspector General. She will discuss the Administration's proposed rebate rule and specifically the anti-kickback statute. I want to thank you for joining us and I also want to welcome Senator Shaheen, who while not officially a member of this Committee, is the co-chair of the Diabetes Caucus with me, and has been extremely active in this area, and we have worked together, particularly on the insulin pricing issue, so we are delighted to have her as an honorary member of the Aging Committee today. Mr. Kouzoukas, we will start with you. STATEMENT OF DEMETRIOS KOUZOUKAS, PRINCIPAL DEPUTY ADMINISTRATOR AND DIRECTOR OF THE CENTER FOR MEDICARE, CENTER FOR MEDICARE AND MEDICAID SERVICES, WASHINGTON, D.C. Mr. Kouzoukas. Thank you, Chairman Collins. The Chairman. I am going to ask you to turn your mic on. Mr. Kouzoukas. There we go. Thank you very much, Chairman Collins, Ranking Member Casey, and other honorable members of this Committee. Thank you very much for the invitation to talk with you today about the critical issue of lowering prescription drug prices in the United States. I am honored to be here on behalf of the Centers for Medicare and Medicaid Services, where I serve as Principal Deputy Administrator and Director of the Center for Medicare. Thank you, as well, to my esteemed colleagues from the Department. It is an honor to be here alongside them as well. Prescription drugs are an important part of health care, as we all know. Patients with diseases that scarcely a decade ago had any treatment options now have access to cures that allow them to lead their best lives. However, patients opportunities to access these drugs are ultimately undermined by numerous distortions which can drive the price of these drugs beyond the reach of patients who need them most. This Administration has been diligently working to root out these distortions and correct disincentives to ensure that true competition allows patients to access the drugs at competitive prices. Earlier this year, the President's Fiscal Year 2020 budget laid out a range of proposals for lowering prescription drug prices, including through reforms to Medicare. Many of the proposals buildupon the President's blueprint, as you called it, that is, the ``American Patients First Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs,'' released in May 2018. This blueprint constitutes the most aggressive and comprehensive plan of action for decreasing drug prices released by any administration ever. It lays out dozens of possible ways that HHS, including Congress and CMS, can together address this vital issue. We are already seeing results from the Administration's efforts to lower drug prices. In 2018, drug prices experienced their single largest decline in 46 years. We also know there is more work to be done, and CMS is committed to doing our part to lower prescription drug prices. Medicare policies can have a wide-reaching impact on health care spending, including prescription drug costs. That is why we are taking steps to unleash innovation, empower patients, and increase transparency across the program. I would like to take a moment to draw your attention some of the proposals in the President's Fiscal Year 202020 budget request. These are of particularly interest, I hope, to the Committee. There is an opportunity for us to work together. The President's proposed budget request for Fiscal Year 2020 includes a comprehensive Medicare Part D structural reform package that would lower prescription drug prices in several ways, including by maximizing the incentives for plans to manage benefits and provide beneficiaries with better protection against catastrophic costs through a maximum out-of- pocket cost. I also want to highlight a few things CMS has already done. Just last month, for example, CMS finalized improvements to Medicare Advantage and Part D, which provides seniors with medical and prescription drug coverage through competing private plans. The policies we finalized will enhance transparency by giving patients greater information on the cost of prescription drugs. The final rule includes a requirement that Part D plans implement one or more real-time benefit tools, so prescribers can discuss out-of-pocket costs for prescription drugs with patients at the time a prescription is written, in the physician office. By empowering patients with more information on the cost of their prescription drugs, our rule will help ensure that pharmaceutical companies have to compete on the basis of prices for patients. We are also pleased with the increased transparency that has come about as a result of CMS' drug spending dashboards. These dashboards reflect CMS' efforts to support innovative, data-driven insights to improve the quality, accessibility, and affordability of prescription drugs. The dashboards focus on average spending and change in average spending per dosage unit to allow the public to understand trends in drug spending. Additionally, CMS is undertaking a comprehensive redesign of the Medicare Plan Finder. We are working to improve the usability of the Plan Finder based on feedback we have been collecting from stakeholders, and we look forward to continuing our collaborations as we move forward with our efforts to modernize this important tool. Some of the other efforts we have already undertaken and are working on to bring down drug prices include giving patients the opportunity to select from competing plans with a selection of physician-administered drugs more tailored to them, so as to drive better deals; putting patients in the driver's seat by helping them engage with plans on the medications they are taking, and what can be done to ensure that the combinations of drugs they are taking are low cost and do not produce negative effects; encouraging biosimilar innovations, by giving each biosimilar its own billing code and lowering biosimilar copays for low-income beneficiaries in Part D; increasing price transparency by presenting data on CMS' average spending per drug dose, and other data insights, and otherwise ensuring that patients know the cost of their drug before they see the doctor or visit the pharmacy; allowing patients to communicate freely with their doctor or pharmacy about the cost of their drug. While CMS has taken these and many other actions to implement the President's American Patient First Blueprint to combat dramatically rising prescription drug prices, we know we have more to do. As we continue our important work in this area, and hopefully our collaborations with Congress, we remain committed to finding ways to promote innovation and patient empowerment in our programs by facilitating transparency and competition. We look forward to working with this Committee, our Federal partners, and most of all, with patients, as we continue to evaluate and implement the most effective ways to approach these issues. Again, thank you for the invitation to speak with you today. I look forward to answering your questions. The Chairman. Thank you very much. Dr. Woodcock, welcome. STATEMENT OF JANET WOODCOCK, M.D., DIRECTOR OF THE CENTER FOR DRUG EVALUATION AND RESEARCH, FOOD AND DRUG ADMINISTRATION, SILVER SPRING, MARYLAND Dr. Woodcock. Thank you, Madam Chairman, Ranking Member, and members of the Committee. I am very happy to be able to talk to you about this important issue today. As you know, FDA does not have a direct role in drug pricing, but we play a major role by driving down prices through competition, and the best example of that is our generic drug program, which has really been empowered since Congress passed the Generic Drug User Fee Program, which is now in its second iteration. Last year, 2018, FDA approved over 1,000 generic drugs. That is a lot of competition, and each year previous had been a record. That was a record and each year previous had been a record, so we are really getting generic drugs out there. Of these last year, 10 percent were first generic approval, so that is the first time competition had been introduced for this molecules, and 12 percent were for complex generics, where there has been a lot of trouble getting competition for complex products. Perhaps they have an auto-injector, they have a device associated with them, or they have some other complexity, so we are making a lot of progress there. We can do more. In 2017, we launched the Drug Competition Action Plan for Generics, and that had a whole menu of activities that we were going to do to try and streamline the process, reducing gaming, and get as many generic products that would be legally appropriate out onto the market. We are taking many steps to promote more competition for complex generics, including helping the companies with developing their drugs. In February alone, we issued 74 product-specific draft guidances, and these guidances were like a cookbook of what you need to do to get a particular generic onto the market, and they explain our expectations of what needs to be done. We also posted the inaugural list of off-patent, off- exclusivity drugs without an approved generic in June 2017, so that gives industry sight into what is available for competition, where there is no competition at the moment. In February, we issued draft guidance on the Competitive Generic Therapies Program, that Senator Collins mentioned. My understanding is by now we have designated almost 200, and we are up to around 10 that we have approved. The new guidance on the Complex Generics Program provides robust information on how drug developers can apply for this designation and when they might be eligible for exclusivity based on it. We are also identifying abuses of the system that can impede competition and doing our part to fix them. We really applaud congressional efforts to remove barriers to drug development and appreciate the work on the CREATES Act, that is looking at access to samples, because generic competitors need access to sample from the innovators in order to make the copies and demonstrate that they are equivalent. There are several proposals in the 2020 budget from the President that also target possible gaming, including statutory improvements to our citizen petitions process, amending the existing 180-day forfeiture provisions to limit gaming in that space, and prevention of 180-day exclusivity parking, we call it, where companies can get exclusivity and then never launch it. The way the statute works now--remember, I am not a lawyer--is that you have to market to make that clock start running, and if you make an agreement or something and you do not market then that can go on. You have never launched and the clock never runs. We look forward to working with your staff on these measures, and we are continuing to coordinate with the Federal Trade Commission, who is a vital partner, in working on anti- competitive issues. Also, we are building a strong framework for biosimilar competition, which is something that has not been present until Congress passed a statute allowing the pathway. That is really key to facilitating greater innovation and competition in the biologics marketplace. Biologics are costly. They account for almost 40 percent of the total prescription drug spend and about 70 percent of the growth in spending between 2010 to 2015, and so since 2010, when Congress enacted the Biologics Price Competition and Innovation Act, creating a pathway, we have approved 20 biosimilars, and we hope more are on the way, and there is a robust pathway for more biosimilars to come. The President's budget recommends a legislative proposal to encourage biosimilar development and innovation and reduced gaming in that space. In closing, there are a lot of efforts that can be done to reduce gaming, to streamline processes, and to get as much competition on the market as possible, and we believe all these efforts will help to reduce the cost of drugs overall. Thank you. The Chairman. Thank you very much, Doctor. Ms. Robinson. STATEMENT OF VICKI L. ROBINSON, SENIOR COUNSELOR FOR POLICY, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF INSPECTOR GENERAL, WASHINGTON, D.C. Ms. Robinson. Good morning, Chairman Collins, Ranking Member Casey, and other distinguished members of this Committee. Thank you for the invitation to testify about the Department's recent proposed rule, which is one part of the Department's strategy to lower prices and reduce prescription costs for beneficiaries. We are in active rulemaking, my testimony today is limited to what is in the proposed rule. It is not intended to predict what might be in the final rule. This morning I want to cover three areas. First, the proposed goals for the rule; second, how the proposed rule meets those goals; and third, the public comments on the proposed rule. Let me begin with the goals. The Department intends for the proposed rule to help lower drug prices and reduce prescription drug costs for beneficiaries. The proposed rule also aims to improve transparency for beneficiaries about the prices they pay. In addition, the proposed rule aims to address the problem that rebates may be skewing decisions about the placement of drugs on formularies, that is, on the list of drugs covered by the beneficiary's plan. Today, under the rebate system, manufacturers typically negotiate rebates with insurance companies and pharmacy benefit managers. The rebates reduce the net cost of drugs for the insurance companies, but the rebate does not necessarily help the beneficiary, because it does not reduce what he or she pays at the pharmacy counter. The proposed rule is intended to shift this dynamic and help move from a system of rebates to one of up-front discounts that lower costs to beneficiaries when they fill their prescription. Second, let me explain what the proposed rule would do to meet these goals. Currently, the safe harbor regulations under the Federal anti-kickback statute, protect discounts and other reductions in price, including rebates that meet specified conditions. The proposed rule would make the following changes. It would remove existing discount safe harbor protection for rebates and reductions in price of prescription drugs given by manufacturers to Part D plans and Medicaid managed care organizations. Next, it would add new safe harbor protections for point-of-sale discounts that are completely applied to the price of the prescription drug at the time the pharmacy dispenses it to the beneficiary. Further, the proposal would add new safe harbor protection for manufacturers to pay pharmacy benefit managers fixed fair market value fees for services they provide to the manufacturer. My written testimony and the proposed rule spell out additional details about these changes. I will close with observations about the public comments. The proposed rule contains analyses of the potential impact on beneficiaries, plans, and others, by CMS' Office of the Actuary and to independent actuarial firms. We received a range of comments about these analyses. In addition, we solicited public comments about many other aspects of the proposed rule. In total, we have received and reviewed about 26,000 public comments from a broad spectrum of stakeholders. We received many thoughtful comments and appreciate the engagement of the public in this rulemaking. Comments addressed a range of important topics, from legal issues to policy goals to practical implementation concerns, and comments expressed strong support for lowering drug costs for beneficiaries. OIG is working with the Department on this rulemaking and a final rule is currently pending review at the Office of Management and Budget. Thank you again for the opportunity to appear today, and I would be happy to take questions. The Chairman. Thank you very much for your work in this area and your testimony. Dr. Woodcock, I am going to start with you. You mentioned in your testimony that biologics account for about 40 percent of all prescription drug spending, so obviously this category is one that we need to take a close look at, and biologics are very important drugs to an awful lot of people. Former Commissioner Gottlieb has said that if all the biosimilars that have been already approved by the FDA were successfully marketed in the United States in a timely fashion, based on the information on the experiences of European countries, Americans would have saved more than $4.5 billion in 2017. Humira is my poster child for what has happened in this area, and it shows what is wrong with the current system. Humira is an extremely valuable drug for rheumatoid arthritis, psoriasis, and other ailments, and it has been on the market in the European Union since October, while the American people, incredibly, must wait until 2023 before the less-expensive biosimilar is available, as a result of AbbVie's anti- competitive patent strategy, so that is 20 years after the drug was first introduced, and that is why I have introduced legislation, and we have worked very closely with the FDA aimed at curbing patent abuses. Everybody wants a period of exclusivity, but it seems to me when that expires the biosimilars should be able to go forward. First of all, does the FDA support the provision of listing, in the Purple Book, all of the patents that a company has to make it easier for the biosimilar to figure out a path forward when the patent has expired? Dr. Woodcock. We are very happy to work with you. The listing would be somewhat burdensome for the FDA, although we would presumably simply play a ministerial role in allowing the companies to list. I think the root cause problem, though, is the adjudication of whether the patents are legal and whether they block the biosimilar product, and for what amount of time, and that really pertains to our patent system and protection of intellectual property, so how far should that go? We have had discussions with the Patent Office about this, because if these are valid patents and they are felt to pertain to the biosimilar then they will block availability for potentially many years after exclusivity has expired and a tentative approval has been granted by the FDA. I think this is a complicated issue, and we are really eager to work with your staff on this issue, because it is blocking availability, and the question is what is the root cause here and how can we untangle this? The Chairman. You have previously testified that the FDA has done 150 referrals to the Federal Trade Commission to take a look at anti-competitive processes without much success. Last May, FDA began publishing a list of inquiries received from generic drug developers who report having trouble accessing testing samples they need. The CREATES Act would help with that, which I have co-sponsored and you mentioned in your testimony. The question for me is, the FTC ought to be taking action when it sees anticompetitive practices preventing generics from getting to the market--paper delay is another outrageous example. Now that the FDA has had a year of experience with this new initiative, is the FTC becoming more aggressive in handling these complaints? Dr. Woodcock. We are really not privy to the FTC actions, so we have referred all of these on our list to the FTC for their evaluation, but the further steps I would refer you to the FTC to, you know, get more complete information. We don't have that. The Chairman. Well, my time has expired so I am going to yield to the Ranking Member, but I would say there is something wrong with the process if there is not feedback from the FTC to the FDA on whether or not they have taken action on a referral from the FDA, so it seems to me maybe that is another area for legislation. Senator Casey. I want to thank the Chairman. I want to thank our panel for being here. I want to focus my first round of questions on Mr. Kouzoukas. I appreciate you being here. You represent the Administration, and I have got a couple of things I want to say about why we are here and how this relates to some larger debates we are having. We are having a debate about how to get the cost of prescription drug prices down, especially out-of-pocket costs. In the midst of all that, this Administration on health care, when you consider the actions taken against the Affordable Care Act and against Medicaid, it can only be described as sabotage/ decimate, to both programs, both the ACA and Medicaid. Over and over again, attempts to undermine both programs, in terms of supporting a lawsuit, in terms of the budget proposals, in terms of efforts to repeal, in terms of giving states waivers, which will undermine these efforts even further, so my point on raising this is simply that these actions are undermining what I think are actually bipartisan efforts to get prescription drug prices down, number one, and number two is, it is having an effect. We were told, as of January--this is a story from Vox dated January 23, ``Under Trump, the number of uninsured Americans has gone up by 7 million.'' It refers to Gallup data--7 million people. Other sources say it is in the millions, at least. While we are doing all this, we are undermining any effort to lower the cost of prescription drugs, because of actions taken against both the Affordable Care Act and Medicaid. We have sent a letter to President Trump where we say, in the opening of the letter, ``The coverage individuals receive through Medicaid and the Affordable Care Act provides protection against extreme out-of-pocket costs on the medications they need in order to remain healthy.'' All these efforts we have undertaken, whether it is filling the donut hole for seniors so their prescription drug costs go down, whether it is coverage for others who are not seniors but they have the protection of health care or the protection of Medicaid or the Affordable Care Act, all of that is undermined, so even if we take steps that are constructive on prescription drugs, all of that is undermined. Madam Chairman, I would ask that both a letter dated June 19th, to the President, on this issue of the connection between actions on health care and prescription drugs be made part of the record. That is number one, and number two, I would ask that a June 11th letter that we sent to the president on the official poverty measure, another effort which, over time, which we say in the letter, will undermine several programs. The official poverty measure is used by Department of Health and Human Services to annually issue poverty guidelines and thresholds. I would ask that both letters be made part of the record. The Chairman. Without objection. Senator Casey. I would ask, and I am almost out of time and I will get back to it, but I would ask this question. What have you done when you and your team are developing and then proposing ways to get prescription drug costs down? What have you done, what has the Administration done to assess the impact that their efforts on Medicaid and the Affordable Care Act, what have you done to make an assessment of how one impacts the other? How can we get prescription drug prices down when we have the Affordable Care Act being attacked morning, noon, and night, and the Medicaid program being the subject of what I would call decimation, because of what the Administration is doing? I give you the rest of the time that I have. Mr. Kouzoukas. Thank you, Senator, and I appreciate the opportunity to hear you out today in person as well as in the correspondence and the dialog I know with which you regularly engage the agency in. I would like to focus a bit on some of the shared--areas of agreement that I think I heard in your question, and I see an area of shared goals here, about access to care and high- quality care, and using competition, really, as the way to get there. I also heard a focus on out-of-pocket costs, and that is very much at the centerpiece--at the center of many of our proposals. I also heard some reference to bipartisan efforts and constructive discussions, and I am heartened, despite--I understand you have a number of other areas with which you disagree with some of our actions, but I also hear you acknowledging, and perhaps it is an opening and an opportunity for us to work together on these bipartisan efforts and constructive discussions. I assure you that as we work on these efforts, internally and externally, we are collaborating, both within the agency and across the Department, to address not only prescription drug prices but access to care, more generally, and that we are also looking forward to engaging in continuing that constructive dialog with you, other members of this Committee, and the Congress. Senator Casey. Well, I would ask again. Did you assess the actions taken by the Administration with regard to ACA and Medicaid, the larger actions that have been ongoing since the beginning? Did you make an assessment of the impact of those actions on your efforts to reduce the cost of prescription drugs? Yes or no. Mr. Kouzoukas. We believe that our efforts to reduce the cost of prescription drugs rely on a variety of authorities that we have, and we are confident and excited about the opportunity to continue to take action that has brought down prices, as they have, and I will---- Senator Casey. That is great. That is great, but I want to know, did you make that assessment? Mr. Kouzoukas. We are working together every day, both within the agency and with Congress to assess the best path forward, and the opportunity, I think, here is for us to work together to ensure that to the extent we do not have authorities---- Senator Casey. Okay. I am over time, but until I hear otherwise I am assuming the answer to my question is no. Thank you, Madam Chair. The Chairman. Senator McSally. Senator McSally. Thank you, Madam Chair. I appreciate your continued leadership on this really important issue. I apologize I missed your verbal testimony. I was meeting with a number of my constituents from Arizona. I have done a 15-county tour in my first 90 days in the Senate, and the cost of prescription drugs has been a top issue for my constituents, regardless of their age, of their situation, economically, as seniors, young people, small business owners, you name it. This is a top-of-mind issue for Arizona families. For example, my office recently heard from a woman from Lake Havasu who suffers from rheumatoid arthritis, so some days she cannot even use her hands or walk. Her prescription costs are approximately $5,000 a month, which is obviously too much for most people to afford or for her to afford. She has decided she can no longer fill these prescriptions and continues to go without the medicine that she needs. She says she carries on with a good attitude but this is really unacceptable that we are leaving patients with no choice but to stop taking the medications. We have seen reports, earlier this year, that 3 out of 10 adults report not filling their prescriptions, that they are left at the pharmacy, even when they show up and see what the out-of-pocket cost is going to be, and again, throughout my State I hear stories like this over and over and over again. Mr. Kouzoukas--is that how you pronounce your name? No. Come on. Tell me. Kouzoukas. Okay. In your testimony you State that under Medicare's Part D new rule would be a requirement that real-time benefit tools that are capable of providing patients with real-time information for their out-of-pocket costs for prescription drugs would be available at the time the prescription is written. I mean, this is, again, the vision, right, that when the doctor says, ``Where should I send the prescription?''--that you are able to pull out an app and you are able to kind of look through it and go, ``I want to go here,'' and it is based on you understanding what your costs are going to be and where you are going to get it filled. I know these are complex issues, but this is where we need to be going. Can you get into further detail on some of the tools and how they would be implemented for that real-time information, and will the rule ensure pharmacies have the right to also disclose lower cash costs? Mr. Kouzoukas. I am so delighted, Senator, that you asked me about that. This is one of those kind of unnoticed items, perhaps, at times, that is a subtle action, but it is part of a bigger picture, part of a comprehensive strategy, of course, as I have mentioned, but it also is a real part, and that is because it goes to that very conversation that the doctor and the patient are having, at the very point where the patient is deciding what it is that they need, and working with their doctor, and at that moment--and I think we have all been in that moment--where you get handed a prescription by the doctor, and I guess---- Senator McSally. Or they say, ``Where should I send it?'' Mr. Kouzoukas. Indeed. Now it is electronic. Senator McSally. Yes. Mr. Kouzoukas. You kind of wonder, in the back of your head, well, how much is this going to cost me? Is it even covered? It feels--like you will sometimes as your doctor and the doctor doesn't know, and what this requirement is, in Part D, is that the plans have a system whereby the doctor can access it through their EHR--at least one EHR has to be compatible with this kind of tool--and identify at that point, what are the formulary alternatives? It is even really critical that it is happening with the doctor's consultation, because then they can clinically discern what kind of medicine is really a kind of alternative, and that is going to really, I feel, change the dialog at that most basic interaction, and it has great promise. Senator McSally. I totally agree. I mean, this is where we need to go. In everything else in our life you are able to have information and then you can make choices and you can do what is best for you, and so, you know, this is America. Why can't we have this tool available now? Like how do you see this being implemented? The data is out there. The information is out there. What is it going to take to make this happen? Mr. Kouzoukas. Well, first of all, I think the support of the Congress as we move forward here, has been important, and I appreciate the opportunity to hear from you and others who recognize the importance of this kind of change, so that is particularly helpful. I will also say that having put it forward, the regulation as we have, we did it in a way that recognized that this is not something that can easily happen overnight, but we pushed very hard to put an aggressive timeline on this. What we would like to see is this kind of technology develop in a way that is truly interaction, and so it does not exist in a silo for only one kind of EHR or one particular plan. Senator McSally. Right. Mr. Kouzoukas. What we are hoping and expecting is that there will be standard that is developed by the industry, and there is a process by which these standards are developed, and we expect our actions are going to really precipitate the development and issuance of that standard so that it is not just--so that the tool is available in all of the EHRs for all of the doctors, in all of the patient rooms, and then it spreads even beyond Medicare, obviously. Senator McSally. Exactly, and that is the vision, again. Again, this should not be that difficult, even though this is a complex issue. The information is out there. We have smart people who can develop these tools, and it should not just be for Medicare. People should be able to have that conversation with their doctor, know what their costs are going to be, to include their cash costs, and then be able to make those decisions as to where to send a prescription and know what it is going to cost them and their family. I look forward to continuing to work with you on this, because we really need to make this happen. Mr. Kouzoukas. Thank you very much. Senator McSally. All right. Thanks. I am out of time. The Chairman. Senator Jones. Senator Jones. Thank you, Madam Chairman and thanks to all the witnesses for being here today. Dr. Kouzoukas, I would like to talk just a minute. One of the biggest things I think that we have seen with the Administration right now is the new rebate rule that is out there, which would change the way discounts are spread, across the board. How would you anticipate that this rule is going to affect the overall price of premiums, and is there going to be a tradeoff for folks with lower drug costs but higher premiums? How will you anticipate the long-term benefit being? Mr. Kouzoukas. Thank you, Senator, for the opportunity to address that particular question. It is an important one with respect to the rebate rule. I know that Ms. Robinson may be able to provide some additional details regarding the mechanics of how the rule works, in terms of its connection to premiums. I will say this, in terms of how it impacts the program and the Part D plans, and when they set their premiums, that what we expect and hope for here is the same kind of dynamic that you get when you go in to buy a car, and if you have had this experience lately--and I have had perhaps the fortunate or unfortunate experience of doing this recently--the salesman is talking about buying some mats, getting the rustproofing, the financing from the dealer, and so on, and imagine if they gave you the price for the package deal but they never can tell you how much the car is going to cost, if you just buy the car. Ultimately, what we are talking about here is changing the dynamic through the mechanics of the rebate rule, that Ms. Robinson summarized for us, to a situation where when you go into the car dealership, when those plans and the manufacturers negotiate against each other and create the kinds of competition we think is fundamentally necessary to lowering drug prices, that they are going to be negotiating over the price of the car, not over the rustproofing, and not over the finance deal, and not over these other things, and the mats, and that is the kind of dynamic we are looking to create, and we think that is going to result in lower cost-sharing, ultimately result in better negotiations, and also result in lower premiums. That is precisely what we are looking for. Senator Jones. Right, but you believe that the lower premiums, it will result in enough lower premiums to--you know, that we are not just going to, you know, lower the cost of the drugs but raise the cost of premiums to where the consumer does not have an effect. You think it is going to affect both? Mr. Kouzoukas. Our view is that ultimately these better negotiations are going to result in all of these positive effects, and that is the spirit with which we undertook this. Obviously, it is a rulemaking so we have a lot of comments to consider, from the OIG perspective, but in terms of the impact on Part D and its program, that is what we are expecting and hoping for as this plays out. Senator Jones. Okay. Well, I may come back to Ms. Robinson on that in a minute. The other thing, I would like to go back to something that Senator Casey said in his opening statement. It does seem--and it does not seem to me that the Administration has any real interest in allowing Medicare, which is the biggest purchaser, I think, of drugs these days, to be able to negotiate these prices, and I am curious as to why there seems to be that resistance. As Senator Casey said, we do not see anything coming out. There are a lot of things, and I want to commend the Administration for their work on this, and I think there are a lot of good things that are coming out, but with Medicare, it would seem like that that is the biggest player in the market, that they could really have a huge effect by negotiating drug prices, and I would like for you to address that. Mr. Kouzoukas. Senator, I think that what I hear in your question is really a focus on negotiation, and the question you are raising, obviously, is who should have those negotiations, but there is clearly an agreement that negotiation and competition are the best path forward, and I am delighted to hear that. Our concern, really, is that as we engage in looking at all the various options for how we can lower drug prices, that we do so in a way that promotes access to innovation as well as negotiation, and that the negotiations are ones that are conducted in the most vigorous possible way. What we have seen is that the negotiations that are conducted by PBMs, the people who do this for a living, have resulted in tremendous amounts of competition. We think that there are opportunities to improve that, obviously, given the nature of the other activities we have been doing, but those kinds of negotiations have been quite intense and are likely to produce the right outcomes. I will also say that also present in our minds, as we consider this situation, is the conclusions drawn by Congress' own budget office, that in order for some kinds of negotiations to play out and achieve--even have the hope of achieving a lower drug price, what ultimately would be required is for the leverage in that negotiation to be driven by the government making a decision about what kinds of drugs people will have access to, and we think that as we look at that current landscape and evaluate the range of alternatives, that giving patients the opportunity to select amongst competing plans in order to achieve the best--who, themselves, are negotiating deals with the manufacturers, is a way to preserve access and get those lower prices through negotiation. Senator Jones. Thank you. Thank you, Madam Chairman. The Chairman. Thank you very much. Senator Shaheen. Senator Shaheen. Thank you, Madam Chairman. I very much appreciate your willingness and Senator Casey's willingness to let me participate in this hearing. As Senator Collins mentioned, she and I co-chair the Diabetes Caucus and we have heard dramatic concerns from people with type 1 and type 2 diabetes across this country about the rising costs of insulin prices. In Medicare patients alone, annual out-of-pocket costs for insulin have more than quadrupled since 2007, and it is not just seniors, as we all know. The skyrocketing cost of insulin is a matter of life and death for diabetic patients of all agents. Many of those patients have tried to ration their insulin because they cannot afford its high cost. In New Hampshire, and I am true it is true in Maine and probably Pennsylvania, we have many of our citizens who are going to Canada to buy insulin because they can buy it cheaper in Canada. Mr. Kouzoukas, what is CMS doing to reduce the sky-high costs of insulin, not just by holding insulin manufacturers accountable but also pharmacy benefit managers accountable for how these costs have risen? Mr. Kouzoukas. Senator, I am glad you gave me an opportunity to talk about this. I will say that diabetes, in particular--and it is great to see you here and have an opportunity to talk about this, to recognize your interest in it, because diabetes is a disaster that affects so many Americans and so many Medicare beneficiaries, and while it affects so many people, I can tell you that it also seems to affect every person in a different way. Every person finds a way to their own treatment journey. Senator Shaheen. I am sorry to interrupt, but I would just point out that for those people who have type 1, they must have insulin or they die, so the idea that there is an alternative treatment to having insulin is just not accurate. Mr. Kouzoukas. Senator, I hope that is not what you got, the impression I was saying. What I was hoping to, perhaps inarticulately, suggest is that the type of insulin, the method of delivery, the way that they handle their dosing, their own management is really something that is an individualized journey for many diabetes patients, and I know that from family members that have diabetes and suffer from it, but I have seen that up close. I think our work in the diabetes space has really been focused on recognizing exactly that, and certainly drug pricing is a big part of it. It is the most key part because of the role insulin plays. I will also point out that we have also undertaken a number of efforts to ensure access to a broad variety of different kinds of insulin delivery devices and other mechanisms by which people can access and make sure that they have the insulin they need or monitor their daily levels and the like, and that is also a critical piece of this. Our work--and I think that this is a good opportunity perhaps to highlight, in diabetes, the opportunity that the rebate offers, for example, because it is a competitive space with a lot of rebates, so that is one area where we would expect to see, you know, a significant change or impact in terms of benefits to beneficiaries, paying the cost share. Senator Shaheen. Do you have any data that shows any changes as the result of what you are proposing on the rebate rule? Mr. Kouzoukas. I think that we can certainly try to work with you to identify what kinds of data you are interested in. We have a lot of data, and a lot of it is out in the proposed rule, but we can also identify what else your data interests are, for sure. Senator Shaheen. Well, I guess it would be--I assume the Committee--I certainly would be interested in how it is going to reduce the costs of insulin and make it more accessible for those people who need it. Mr. Kouzoukas. Indeed, and we share your interest in that. I think that--and that is really just one part of a comprehensive strategy, so we will be delighted to work with you on that. Senator Shaheen. Thank you. Dr. Woodcock, I am going to go back to the point that Senator Collins made and that you were confirming when you talked about the importance of approving biosimilars to provide competition for biologics, because that has been where the real increases in costs have been in recent years, and my recollection is that the legislation that set up a method for approving biosimilars was part of the Affordable Care Act when it was passed. Can you tell me if the effort to strike down the Affordable Care Act will also strike down that pathway for biosimilars? Dr. Woodcock. Well, I am not a lawyer, but my understanding of the law is that there are many ifs in this. It would depend on all sorts of things about the ruling, what the ruling was, so I can't predict. Senator Shaheen. We do not know what the impact would be. Dr. Woodcock. Yes, I do not know. I cannot predict. Senator Shaheen. It is possible that like many of the other aspects of the Affordable Care Act it will strike that down as well. Dr. Woodcock. I do not know. Senator Shaheen. Thank you, Madam Chair. The Chairman. Thank you, Senator. Before I call on Senator Braun I just want to add a comment to what Senator Shaheen said to Mr. Kouzoukas, and that is insulin has been around since 1921, and when we hear from constituents who are now seeing the price having increased by, on average, 240 percent over the past decade, I realize there are different kinds of insulin but that is just an outrage, and I am going to followup on the suggestion that the Senator from New Hampshire made on asking you, in writing, to give to us more of an explanation of how the rebate rule would have a positive effect on that. I personally believe it would, but I want to get that from you, so perhaps we can followup on that. Senator Braun. Thank you, Madam Chair and Ranking Member Casey. I am on the Health Committee as well and had basically this same discussion yesterday. Every time I get involved in one of these discussions I want to make sure that the industry is aware, and that is from health insurance to pharma to hospitals and even the people that make their living in the business, doctors and nurses, with the exception of the latter, where I think they are caught in a swirl just like in big agriculture, we increasingly have huge corporations that dominate, you know, the landscape. At least in agriculture there is transparency and farmers know what they are buying and paying for. In health care, when I tackled this issue as a CEO of a company 10 years ago, and I look at this, efforts to further competition and increase affordability, there is no other industry that I am aware of, especially one has large as health care, that needs the nudging that we are trying to give here on aging and in the Health Committee. I would like to put all the CEOs on notice that now control the dynamic in health care, that have delivered the product that we are all grappling with, that we know has excellent features to it, where we do things really well in this country when it comes to health care but it just costs too much, and hidden behind, universally, opaqueness, not embracing competition, like all the rest of us do in running our businesses in other sectors of the economy. Thank goodness we are taking this on as a real issue. Until, I do not know that we here will accomplish what needs to happen quickly enough to stave off, you know, what may be solved through some type of crisis down the road, but I am at least glad we are taking about it. Focusing in on PBM rebates, Senator Romney and I have got a bill that does something similar to what Alex Azar is putting out as a ruling, you know, for Medicare and Medicaid. My analysis of PBM rebates is why do you have a middleman involved, number one. I do not know of one other supply chain, in any other industry, that has a middle man that is hired to determine how margin gets divvied up to get it through the supply chain. That is archaic. It is not needs. That should ideally be done by the people that make the product, big pharma, and the distributors, and the dealers, the pharmacists. The only part of that network that looks to me like it is functioning would be at the pharmacy level, where, in most domains, you have still got lots of choices. It gets murky and confusing when you look at the distributors, and especially the people that make it. I size up PBM rebates as around $150 billion a year, of which $85 billion of it, most of the rebate, gets eaten up by the costs and the profits of a middleman that is unneeded. Whoever would like to respond to it, do we need PBMs? Do you think if we shed light and transparency on it that this can get solved, and drugs can get priced at a reasonable level without the need of an artificial middleman that exists in no other supply chain? Anybody that wants to tackle it. Mr. Kouzoukas. I can start sir. Senator Braun. Thank you. Mr. Kouzoukas. Thank you, Senator, for that. The question about PBMs and their role, I think the answer, from my perspective, really is that we need to ensure that there is competition in a market, and that may or may not include PBMs. It does not necessarily have to. The ultimate question should be, though--the answer should really lie and be driven--we should get to the answer by looking to consumers and competition to lead us to the right path, and I think you have identified, in your question, very much some of the concerns we have about how the system that has grown up around prescription drugs and Part D, perhaps unintentionally in many ways, as creating its own kind of perverse incentives. It is not an example we think, necessarily, of the market driving to a conclusion and ordering itself in a way that your business is accustomed to, before you got here. What we seek to do, within the confines of the government program--it is obviously a government program that we are administering here and the Congress has given us the task to run--how do we make sure that there is as much market competition so that that gets us to the right answer, and that is what we are looking for, and as to your legislation, we are always interested and willing to work with you and others on potential legislative approaches as well. Senator Braun. Thank you. I am out of time. If there is another round of questions I would have one, in especially addressing the consumer component, where I think it has been an atrophied health care user that has been, you know, not participating in his or her own well-being as part of what drives most other markets as well. I will save that for a second round, if we have it. Thank you. The Chairman. Thank you, Senator. Senator Blumenthal. Thanks, Madam Chair, and thanks for holding this hearing. Thank you all for being here. There is no disagreement that drug prices are too high. There is no shortage of proposals to deal with it. I have offered a number of them myself, the CURE High Drug Prices Act that would compel pharmaceutical drug companies to lower their prices if they are found to be engaging in price gouging. Another is the Affordable Prescriptions for Patients Act, which I introduced along with Senator Cornyn, that would take action against egregious patent abuses like product hopping and patent thickening. These terms have probably little meaning to most Americans but they raise the prices of prescription drug prices, as probably you know, and other tactics are similar anti-competitive. But I want to come back to the price of insulin, because here is a very simple drug. As Senator Collins observes, it has been around for decades, almost a century. There is nothing novel about it. It is not a wonder drug, and the prices continue to increase. We are not talking about a plateau. The prices are continuing to rise astronomically. Mr. Kouzoukas, what are you going to do about it? Tell me in simple English what you think the causes are and what the remedies are that you would undertake? Mr. Kouzoukas. Senator, I recognize, really, your long history and passion for consumers, and I think that the kinds of approaches that we are taking today I hope are ones that we have common ground on and share appeal--you have some shared appeal for, because they are really focused on consumers and the bottom-line impact on them. I will say that a big part of that strategy is the proposed rule that is around rebates that ultimately---- Senator Blumenthal. Will that solve it? Mr. Kouzoukas. That is part of a multilayered---- Senator Blumenthal. What else is necessary? Mr. Kouzoukas. We also are working very hard to implement a number of changes in how the Part D program is administered, and have proposed a number of them to Congress. I will give you a few examples. One is the model that we recently put out that provides an incentive or removes a disincentive, in some ways, for plans to maximize their negotiation in the catastrophic phase of the Part D program. That is one that we believe has promise to change the dynamic when it comes to a patient who has come to the very end of their very high-cost drug spending over the course of a year, and diabetics often have a lot of comorbid conditions so they are often going to be people who are going to be affected by the catastrophic phase of the Part D program. We also have implemented the legislation that this Congress, and I know this Committee and many of you have been helpful in getting this legislation passed around gag clauses, to make sure that patients know that they can pay cash prices if they need to in a way that is lower than what they would have otherwise been charged as a result of some of the distortions in the pricing system. Then I would also--I really, most of all, though, would really be remiss not to highlight that the entire package of the President's budget, it represents a multilayered approach to prescription drug prices. It is going to have, we think, the most promising opportunities to address the situation you described, and that it is one that, I think, that there are many elements of it that I know have a lot of bipartisan support, and so we are quite hopeful that we will have the opportunity to work with you and others to get to exactly that place. I know Dr. Woodcock may have something to add there as well. Senator Blumenthal. Before you pass the microphone, so to speak, can you assure us that a year from now, when we are sitting here, and if you come back, that the prices of insulin will be lower? Mr. Kouzoukas. We are working to assure that every day, and we are really delighted about changes that we have already seen, a corner start to turn, and we are working every day to make sure that exactly that happens--a year from now, a month from now, every day, and any day. Senator Blumenthal. Would you favor Medicare negotiation of drug prices? Mr. Kouzoukas. We think Medicare, Senator, does negotiate for drug prices. It does it in a way that brings about really effective negotiations. It drives down prices and it also ensures access to broad types of drugs. Senator Blumenthal. You think it is doing enough now to negotiate? Mr. Kouzoukas. We think that there are opportunities to improve the negotiation and that we have definitely worked to create new levers and new opportunities for negotiation to maximize that, and we are also---- Senator Blumenthal. Do you support legislation to increase the authority to negotiate? Mr. Kouzoukas. We would be certainly interested to understand a little bit more about what you have in mind, but we are always interested in ways to maximize negotiations. Senator Blumenthal. I am out of time. I know Dr. Woodcock may have had another response. The Chairman. Dr. Woodcock, why don't you respond and then we will move on. Dr. Woodcock. Certainly. Insulin has been regulated as a drug, not a biologic, although it is a protein hormone, and Congress put in place deeming next March. They will be deemed-- insulins will be deemed to biologics that will open them up to biosimilar competition. We have, again, a robust pipeline of interests in biosimilars for various insulins, because although they are--it is an old molecule, there are many delivery systems and modifications to insulin that have made them easier for diabetics to manage their blood sugar effectively, so there are a variety of products out there and they will be eligible for biosimilar competition come March, after they are transferred as biologics. Senator Blumenthal. Thanks, Dr. Woodcock. Thank you, Madam Chair. The Chairman. You are welcome, Senator. Ms. Robinson, in your written testimony you mentioned that the President's proposed budget request includes a provision that would increase competition by reducing average sales price base payments when a drug manufacturer takes anti-competitive action. An example of that is pay-for-delay. What exactly would the rule do to prevent pay-for-delay agreements? Ms. Robinson. Senator, I think that may be from one of my colleagues' actual written testimony. I will say that this rule really focuses on the rebate stream of payments and the discounts. It does not address the pay-for-delay issue that you are mentioning, and I apologize. The Chairman. If was not your testimony, then I have a feeling it was Mr. Kouzoukas' testimony, so could you answer that question for me? What specifically does the President's proposal do to prevent these kinds of anti-competitive behaviors like pay-for-delay? Mr. Kouzoukas. Chairman Collins, the President's proposal-- and I will say as with all the things in the budget, it is part of a comprehensive package, so it is one part among many that we think need to be considered in concert. It would essentially reduce payment for innovator drugs when the ASP--from ASP plus 6 to ASP minus 33 percent, when a manufacturer files a pay-for- delay agreement or takes another anti-competitive action. Now the details, as with many budget proposals, are ones that we believe that we would be delighted to have an opportunity to work with Congress on to fill in, but the basic notion and the gist is that we think that the ASP mechanism is one that provides an opportunity to address this kind of anti- competitive behavior that you and others have identified as a concern. The Chairman. You would use the reimbursement system, essentially, that is available under the Medicare system to penalize a company that pays a generic not to come to market. Is that correct? Mr. Kouzoukas. Chairman Collins, I do not know if I would use the word ``penalize.'' It is perhaps to-- The Chairman. Well I hope if we are going to average sales price plus 6 to average sales price minus 30 percent, or whatever it was that you said, I think most companies would view that as a penalty. Mr. Kouzoukas. I understand, Chairman Collins. The Chairman. I am not against it. Believe me. I think pay- for-delay is outrageous. Mr. Kouzoukas. I think our view might be that we are pricing appropriate to what we think is a dynamic that is great in the marketplace, and that if it is going to be a situation where the ASP is essentially undermined by the anti-competitive action that we should recognize that in our pricing, but certainly I imagine some might view that differently. The Chairman. Let me move on to another issue. At our previous hearings we heard from patients who have monthly drug costs that are completely unpredictable and can range significantly, depending on their benefit design, where they are in reaching their deductible, or where their spending places them in the Part D stages. Others who take extraordinarily expensive drugs go through the benefit stages very quickly. One witness who was diagnosed with multiple melanoma 3 years ago testified that she went in and out of the donut hole in January, paying $4,950 for the first month and then $640 every 28 days for the rest of the year for the drug that she needed. She had refinance her home to afford the cost of her medication. My question to you is this. What is the best way to reform the catastrophic benefit so that it helps patients without creating any perverse incentives in our drug pricing system? Mr. Kouzoukas. Chairman Collins, first I would like to note that I empathize with the letters and the testimony that you have heard. Really, these are the kinds of stories that we get every day as well, and it is very much a big part of why we do what we do and are working so hard to address this prescription drug dynamic. The catastrophic phase is an important piece of this because the people who are most affected, sort of the worst situations are the ones who have the high drug costs, and that puts them into the catastrophic phase. I will say that we are testing, in our Part D modernization model right now, a change whereby prescription drug plans have an opportunity to come in and offer a--give an incentive, if you will, in order to get even bigger discounts in the catastrophic phase, and to do that in a way that will drive better negotiation. I will also say that in our budget proposal, as one part among several, we have a protection for maximum out-of-pocket costs as well, and we think that what is important---- The Chairman. That is lower than current law? Mr. Kouzoukas. Indeed. In Part D there is not currently an out-of-pocket maximum. The Chairman. Well, there is a matching system that comes into play. Mr. Kouzoukas. Of course, Chairman Collins, and so it is broader than current law in terms of the proposal, and I will say in terms of the incentives it creates--which I think is an important part of this, and I recognize that you are pointing out some of these tradeoffs. Every policy that we make here, in this kind of program, there are going to be these tradeoffs, and that is why the budget proposal is part of a package. There are other things in that package that will essentially work in concert to ensure that we have both negotiation and access, and that we address any distortions or misincentives. The Chairman. Senator Casey. Senator Casey. Thanks. Ms. Robinson, I will start with you. I wanted to refer to a Pennsylvania report. This is from 2018, and the auditor general of the State uncovered a troubling practice of spread pricing by our state's pharmacy benefit managers in allowing private companies to profit at the expense of State Medicaid programs and taxpayers. This report found that in 2017, three such middlemen got millions in profits from Pennsylvania's Medicaid program by using spread pricing tactics. Medicaid, as I think you would agree, we all agree, is not a program for which private companies should be permitted to skim off the top in order to pad company profits or the wallets of CEOs. The Office of Inspector General received a letter from the Finance Committee leadership, written by Chairman Grassley and Ranking Member Wyden, in April of this year, urging additional, ``transparency and oversight,'' into these spread pricing practices that were cited in Pennsylvania. Can you comment on the status of this request at the HHS OIG? Ms. Robinson. Yes, I can, Senator Casey, and I appreciate the interest in our work. We have that inquiry and we are in the process of thinking about what new work we would do in this area to look at spread pricing in Medicaid, you describe. We have a team of experts actually doing some research, including they have reviewed the Pennsylvania State auditor's report that you mentioned and a variety of other things, so we are in the early stages of looking at what work we would do there. We would be happy, first off, to meet with you or your staff to hear more about your interests, and certainly happy to keep you apprised as that work develops. Senator Casey. Thanks. Any sense of the timing on this? Ms. Robinson. I am sorry. I do not have any sense of timing right now. Senator Casey. I was hoping I could report back to the committee. Ms. Robinson. I would be happy to followup after, if I can, on that. Senator Casey. We will, and thank you very much. Mr. Kouzoukas, I have one fact check but also, I think, an area of agreement. You mentioned in your opening about the cost reduction of prescription drug prices, and I think what you are referencing is something the President said in the State of the Union. The Associated Press quoted the President as saying, ``As a result of my Administration's efforts in 2018, drug prices experienced their single largest decline in 46 years.'' You made reference to that in your opening. I just wanted to point out what the Associated Press found. They found, ``The Consumer Price Index for prescription drugs shows a 0.6 percent reduction in prices in December 2018 when compared with December 2017,'' and that I think that is the reference the President is making. However, the same index showed a 1.6 percent increase when comparing the full 12 months of 2018 compared with the entire previous year, so I hope the Administration will clarify that that reference he makes and that you have made is a December- to-December comparison as opposed to a year-to-year. I think there is an area of agreement here when it comes to drug spending dashboards. As you know, Chairman Collins and I have introduced a bill to codify and strengthen the Medicare/ Medicaid prescription drug spending dashboards. This was started by the Obama administration to shine a light on how much the Federal Government spends on prescription drugs. The Trump administration expanded the tool to show what thousands of prescription drug costs taxpayers, and the need for transparency is obvious, I think, and this is one area where we can make some progress and do it in a bipartisan way. I just wanted to ask you about your sense of the value of these dashboards, and tell us, if anything, what the administration hopes to do about it--to strengthen it, I should say. Mr. Kouzoukas. Thank you, Senator. As you noted, we have been hard at work to expand the dashboards and we view it as really an opportunity, one part of many, to build a bipartisan approach, and all of these efforts are ones that we expect will sort of accumulate and will buildupon themselves. It is something that has been a priority for the Administration, is to make sure that we provide an expanded opportunity for people to get access to this kind of information, and it certainly is potentially useful to beneficiaries and patients as well, but it is also really important for some of the other stakeholders and other parts of the industry where, if we are not going to get the kind of transparency through a market, as Senator Braun had indicated earlier, then bringing this transparency through the data that we have access to, and so we are always working to identify ways to even further enhance what we are already doing. We are interested in hearing from you and others on the Committee on how we can do that even more intensely, but we are excited about the opportunity that the dashboards present and are grateful for the support. Senator Casey. Thanks very much, Madam Chair. The Chairman. Thank you. Senator McSally. Thank you, Madam Chair, and my next question is for Dr. Woodcock. You talked about the importance of biosimilars in your testimony. We know that it is a crucial tool for so many patients, but earlier this year it was released that those specialty drugs are taken by a relatively small share of Part D enrollees. Spending on the drugs has increased and accounts for more than 20 percent of Part D spending. The FDA is continually approving biosimilars but fewer than half are actually showing up on the market, so I share your concern about a large portion of these being approved and never making it to patients, so I was wondering if you could elaborate on what you think is holding that up and what else we could do to get these approved biosimilars to patients so that they can use them. Dr. Woodcock. We are not totally sure because we do not have total visibility into what companies do after we would approve a biosimilar. We are aware that some of these are caught up in patent disputes, though, and as was discussed earlier, patents can run much longer than any exclusivity and fights over those can delay availability for a long time, but we are not fully clear on the different reasons that these drugs do not reach the market. In fact, when we approve generic drugs, often they are not launched in the United States, even after we have approved them, and the reasons are business reasons and they are not shared with us. Senator McSally. Is there anything else that we can do, or you can do, in order to better understand, other than the very significant patent discussions that we have had about, you know, really allowing competition to truly be there once the patent has expired and to stop the abuses of patents? Is there anything else that can be done? Dr. Woodcock. We hold meetings with the industry to try elicit an understanding of these things, and we will continue to do that. My impression, though, is that the patent issues are the most pressing right now, and probably the most responsible for the failure to launch these. It is very expensive to develop a biosimilar, unlike, say, a generic, and that is a lot of investment and then not to seek the market. There have to be substantive reasons. Senator McSally. Great. Thank you. Mr. Kouzoukas, any other perspectives on that issue? Mr. Kouzoukas. Of course. Thank you, Senator. The question of how we can encourage greater biosimilar innovation and adoption is one that we work collaboratively with the FDA on. Clearly it starts with what the FDA's work is, in terms of getting an approval process, and the tremendous work they have done to create a new biosimilars pathway has been a big part of this, and it would not be even possible to have this conversation without it. In terms of what happens once that drug gets to market, that is where the Medicare program often can play a big influence. We are pleased that we have taken a few really important steps already to encourage greater biosimilar innovation adoption. One is that we changed the way that we assign separate codes for biosimilar payment. It sounds like a rather obscure change, I suppose, but really it is quite important, because the way that biosimilars had been previously paid for and priced in Part B of Medicare is that they essentially were all lumped in together, and that did not encourage additional innovators to come into the market, so we think that was an important step and we are really excited about seeing it play out over the long term. It will not be an overnight kind of thing because investors have to line up behind putting that kind of infrastructure in place, as Dr. Woodcock pointed out. We also made some changes to the way that we--cost-share, that we oversee cost-sharing for low-income beneficiaries when they take a biosimilar. We essentially changed the rule so that a biosimilar is treated as a generic for those low-income beneficiaries. That is a good part of the market and so it is important there that that kind of change continue to play itself out, and then we also have, with respect to biosimilars, a budget proposal that would eliminate cost-sharing for generics and biosimilars. It is part, again, of a larger package that needs to be viewed in concert, but we would be delighted to have the opportunity to work with Congress on passing that, and that is just really a thumbnail sketch. Senator McSally. Great. Thank you. I appreciate it. Thank you, Madam Chair. The Chairman. Thank you. Senator Jones. Thank you, Madam Chairman. Ms. Robinson, I would like to give you an opportunity to talk about the rebate rule a little bit and followup on the question I asked Mr. Kouzoukas about kind of the tradeoffs between potential rising premiums and a lower cost. Can you just--I know you are limited on somewhat of what you can say, but do you have any thoughts about that? Ms. Robinson. Thank you, Senator, for the question. I think what I can draw from is what is in the proposed rule, some of the modeling that was done by the actuaries, looking at this rule. It is difficult to know and to quantify accurately what the effects are going to be. There is a lot of uncertainty. It is a very complex industry and a complex rule, but what some of that modeling shows is that overall, on average, beneficiaries would have net reduction in out-of-pocket costs, the combination of premiums and what you pay at the counter, as a result of this rule, but the results would very much be different for different beneficiaries, so they did model increases in premiums but also decreases in out-of-pocket spending, particularly for sicker beneficiaries, beneficiaries that take high-cost drugs that are currently subject to rebates, and when you netted out the savings at the counter, net it out against the premiums, the modeling shows an overall savings, in general. There are actually multiple scenarios modeled here so it is a bit complicated. The premium estimate increases for 2020, for example, range from about $3.20 a month to $5.64 a month, per bene, per month, so it is a fairly complex scenario. We have solicited public comments on all of this modeling, and have all of those comments in front of us. Senator Jones. Would you anticipate some kind of monitoring over the course--and let's assume this rule goes into effect-- some type of monitoring to make sure that PBMs just do not, you know, say, well, you know, this is going to cost us profits so we are just going to artificially boost the premiums, you know, to keep our profits, you know, the PBM profits. Is there going to be a monitoring in place to monitor that? Ms. Robinson. I think it is going to be incredibly important that the Department monitor what happens here. We want to be sure that these rules, if they are finalized, work the way they are intended to work, and if things go differently than intended, corrective actions and things can be done. I think it is going to be incredibly important for the Department to monitor what happens if this rule is finalized. Senator Jones. All right. Thank you. Dr. Woodcock, we seem to still be seeing rising costs in even generic drugs over the last couple of years, so what do you see we can do to incentivize manufacturers to enter the generic market, encourage the competition, and will that drive down the prices by doing that or do we need to do something more? Dr. Woodcock. The generic drug price rises often relate when there is a sole source, where there is no competition, and this is related to shortages. Why do we have markets where there is not really a market? There is one market entrant. Our Drug Shortage Task Force is really looking at this, to try and figure out the root causes of this distortion in the market, or market failure. Obviously areas where robust competition, where we have four or five competitors offering the same drug, the prices of those drugs are very low, but where there is a single manufacturer making that drug, and it may be going in and out of shortage, that is where we see the prices going up. Senator Jones. Okay. All right. That is all I have. Thank you, Madam Chairman. The Chairman. Thank you. Senator Braun. Thank you, Madam Chair. Ending on that point there, that is, again, very simple. When there is one supplier the price is going to go up. You know, we are nudging the industry with this conversation, and I am hopeful, like I said earlier, that they are going to get the message and help us out. Let's assume we get the industry to be transparent and competitive. It's a big assumption. I want to turn where we ended up a while ago, the consumer. In my own plan, when I took this on 11 years ago, it was an atrophied health care consumer that would have described my average employee. You know, they, of course, were concerned about their premium contribution staying low. That is the really only thing out-of-pocket if you take care of yourself, but what I tried to tell them, and I need you to help me do some of the heavy lifting, there is no market that works well, even when it is transparent and competitive on the supply provider side, if you do not have an engaged consumer. Look how often you see people at the grocery store looking at their phone to save 20 cents on a $2 item. We do not have that currently in health care. I created an atmosphere to where I told them I would hold their costs down in the future, which was an idea. I could not guarantee it but I did it. I had to change a behavior to get my employees, health care customers, eventually, engaged. Do you think that is possible when health care has been so paternalistic, whether it is through Medicare, Medicaid, or employer-provided plans, where most individuals are only interested in how low their co-pay is, to avoid any skin in the game? I fixed it and it has worked. Do you think we can get the other side of the equation involved, that is the individual that uses health care, to help transparency out if, in fact, we get it? Anyone that wants to comment on it. Mr. Kouzoukas. Senator, I can start, for sure. You know, I am really excited to hear about your personal story of leadership within the commercial enterprise or business in terms of how to approach this together with employees, and I lament, really, that we put you in a situation where you had to find your way to that, and so many employers, I think, we hear from, feel like they are struggling, swimming upstream against a system that is designed to make it harder and harder for them to get a better deal for their employees, and yet the employees rely on them for that health care. To answer your question, I think just very directly, not only is it possible, it is necessary, and I believe, ultimately, inevitable, that ultimately what we are talking about here--and this is why our strategy just fundamentally relies on consumers and patients, what we are talking about are people making decisions for their own health care. They are the ones that are ultimately going to end up in the hospital, or not be in the hospital, or shorten their life, or being able to spend time with their loved ones or not, and so as we empower them, I have absolute faith that people want to live healthier lives. They want to live better lives. They want to live longer lives, and even sometimes if they are going to make some tradeoffs, they need to be in control, and when we give people that information, when we give them a taste and an ability to make those decisions for themselves, I think we are all going to have to run to get out of the way, because they are going to be checking their phones and doing everything else in health care, and demanding, really, the kinds of accountability and choice that they are accustomed to in the rest of the economy. All we need to do is really start getting out of their way. Senator Braun. That is what we did in my company. Dr. Woodcock. Dr. Woodcock. Well, we have proposed reform in our self- care part of drugs, which is the over-the-counter. We regulate maybe 100,000 different drugs that are offered to consumers for self-care, but that whole system is stuck in the 1970's, and we cannot have any innovation within that monograph system. As a physician, I would say I think there is a generational issue here. My older patients often wanted ``Doctor Knows Best,'' okay, but the rising generations really want to be active participants, and there is no better way for more minor conditions or certain conditions than to actually have safe and effective drugs available to you over the counter. You do not have to take off work, you do not have to make a doctor's appointment, you do not have to pay for parking, and you can select amongst options, but that has to be done so that it is safe and effective for the person to use that product, so we are very dedicated to self-care and the rising self-care industry, and we believe that the OTC reform--and, Senator Casey, thank you for your leadership--we believe that will help bring that about. Senator Braun. Ms. Robinson, would you want to comment quickly? Ms. Robinson. Yes. I do not know that we have a view on your exact question but I will say that in the Inspector General's Office we know we need to be prepared to oversee a health care system that is going to be more technologically driven, more consumer driven. It is going to be much more in that vein, and so we are preparing to be ready oversee that kind of health care system. Senator Braun. In fact, I know from my own experiment, when you own your own well-being, and when you have skin in the game, and you make tools available, that are like pulling teeth to get available, it can work. You know, we have done it now 10 years running, so thank you for your comments. The Chairman. Thank you, Senator. I want to thank all of our witnesses today for your work in developing and advancing policies to lower the cost of prescription drugs for all Americans. Today we have examined Federal efforts to foster more competition, transparency, and increase affordability. I salute all of you for your efforts and it is important that they continue as the Senate and the House act in this area. Committee members are going to have until Friday, June 28th, to submit questions for the record. I know that I have got a couple I want to submit. Again, I want to thank our witnesses, Ranking Member, all the Committee members who participated, as well as our very hard-working staff. I have to go to Appropriations for a mark-up on the supplemental appropriations bill, so if the Senator will excuse me for not being here for his final comments, I am going to turn the gavel over to you. Senator Casey. Wow. The Chairman. I am little nervous about this, but I trust you. Thank you all for being here today. Senator Casey. Madam Chair, thank you very much for the hearing, and as you leave I will make sure the gavel goes back. I do want to thank the Chairman for calling this hearing and for giving us a chance to talk about this important issue. I want to thank our witnesses for being here, for your testimony, for the work you are doing on these important issues. I will say, for the record, that I did not have a chance to--or I did not take the opportunity, I guess, to ask Dr. Woodcock a question, and I feel really badly about that, not only because she is so capable but she has an extra qualifier for today. She is a native of Blair County, Pennsylvania. She has got a Bucknell degree and a Penn State degree, or teaching? Dr. Woodcock. Post-medical school, so teaching. Senator Casey. Teaching. I owe you one. Next time we will ask you every single question, but thanks for the testimony. I think we can all agree, in a country as prosperous as ours, we must do better on this issue of lowering prescription drug costs. No family should be forced to carry what I called earlier the heavy bag of rocks of child care costs, the cost of college, and then, on top of all that, the heavy back of rocks called prescription drug costs, on their back. No family should have to endure that many costs, just to name a few. We heard what the Administration is proposing to do about it and we are grateful the Administration is focused on this. We have discussed solutions that Members of Congress in both houses are working on. We have got to get those enacted into law. That is a whole other challenge. We must do what 95 percent of Americans demand of us and pass a law that allows Medicare to negotiate drug prices. We must not lose sight of the continued threats to the very programs like Medicaid and the Affordable Care Act, that I mentioned earlier in my question, that ensure families affordable access to needed medicines, and more, and I think that is a critical part of this debate. We cannot be focusing on lowering drug prices only and then forgetting about the supports for keeping those prices down that come through the Affordable Care Act and Medicaid. We want to thank our witnesses, and with that, with my left hand, I will gavel us out. Thank you. [Whereupon, at 10:39 a.m., the Committee was adjourned.] ======================================================================= APPENDIX ======================================================================= Prepared Witness Statements ======================================================================= [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] ======================================================================= Statements for the Record ======================================================================= [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] [all]